ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")
Ondine President increases shareholding
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Nicolas Loebel, President and CTO, has purchased 25,000 shares ("Common Shares") in the Company at a price of 12.6 pence per Common Share on 05 February 2025.
Following this transaction, Nicolas Loebel holds 3,538,991 Common Shares representing 0.8006% of the issued share capital of the Company.
Enquiries:
| Ondine Biomedical Inc. | |
| Carolyn Cross, CEO | Via Vane Percy & Roberts |
|
Strand Hanson Limited (Nominated & Financial Adviser) |
|
| James Harris, Richard Johnson | +44 (0)20 7409 3494 |
|
|
|
| RBC Capital Markets (Broker) |
|
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| |
|
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy, Amanda Bernard | +44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Nicolas Loebel |
| 2. | Reason for the Notification | |
| a) | Position/status | President and CTO (PDMR) |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Ondine Biomedical Inc. |
| b) | LEI | 9845005B69E07CGF4A56 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument
| Common shares |
| Identification code | ISIN: CA68234M2058 | |
| b) | Nature of the transaction | Share purchase |
| c) | Price(s) and volume(s) | 25,000 shares at 12.6 pence each |
| d) | Aggregated information: ·Aggregated volume ·Price | N/A
|
| e) | Date of the transaction | 05 February 2025 |
| f) | Place of the transaction | AIM |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.